Atherosclerosis and comorbidity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article considers the problem of comorbidity which includes cardiovascular diseases of atherosclerosis origin. Use of statins is pathogenetically grounded for such category of patients. Also, due to appearance of the large quantity of generics, the synthetic statins-based medicaments (atorvastatin and rosuvastatin) got the mostly wide distribution. Each of them has a big evidentiary base. Data of clinical research works, and also systematic reviews and meta-analyses, proving the advantages of atorvastatin and rosuvastatin use in patients with different comorbid combinations are introduced.

Full Text

Restricted Access

About the authors

Julia V. Lukina

National medical scientific research centre of preventive medicine

Email: yuvlu@mail.ru
PhD, leading researcher of preventive pharmacotherapy Department

References

  1. Salive M.E. Multimorbidity in older adults. Epidemiol. Rev. 2013; 35: 75-83.
  2. Oganov R.G. Vascular comorbidity: general approaches to prevention and treatment. Rational Pharmacother. Cardiol. 2015; 11(1): 4-7. (In Russ.) Оганов Р.Г. Сосудистая коморбидность: общие подходы к профилактике и лечению. Рациональная фармакотерапия в кардиологии. 2015; 11(1): 4-7.
  3. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М., 2005. 1528 с.
  4. The Task Force for the Management of Dyslipidaemias of the European Society of Car-diology (ESC) and European Atherosclerosis Society (EAS). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016; 37: 2999-305.
  5. Borghi C., Cicero A.F. Which statin is the ideal statin for polymedicated patients? Clin. Lipidol. 2012; 7(Supl.1): 11-6.
  6. Weng T.C., Yang Y.H., Lin S.J., Tai S.H. A systematic review and meta-analysis on the therapeutic equivalence of statins. J. Clin. Pharm. Ther. 2010; 35: 139-51.
  7. Tiwari A., Bansal V., Chugh A., Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Exp. Opin. Drug Safety.2006; 5(5): 651-66.
  8. Hamelin B.A., Turgeon J. Hydrophilicity/Lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacol. Sci. 1998; 19(1): 26-37.
  9. Smith M.E.B., Lee N.J., Haney E. et al. Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5. 2009 by Oregon Health & Science University Portland, Oregon - 523pp. Available at. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0008782/pdf/PubMedHealth_PMH0008782.pdf.
  10. Nicholls S.J., Brandrup-Wongsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy ot increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 2010; 105: 69-76.
  11. Wlodarczyk J., Sullivan D., Smith M. Comparison of benefits and risk of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am. J. Cardiol. 2008; 102: 1654-62.
  12. Linton A., Garber M., Fagan N.K., Peterson M.R. Examination of multiple medication use among TRICARE beneficiaries aged 65 years and older. J. Manag. Care Pharm. 2007; 13: 155-62.
  13. Schuler J., Dückelmann C., Beindl W., Prinz E., Michalski T., Pichler M. Polypharmacy and inappropriate prescribing in elderly internal medicine patients in Austria. Wien Klin. Wochenschr. 2008; 120: 733-41.
  14. Medicines and Healthcare products Regulatory Agency. Statins: interactions, and updated advice for atorvastatin. Drug Safety Update January 2008; 1(6): 2.
  15. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-81.
  16. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Symeonidis A.N. et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr. Med. Res. Opin. 2004; 20(5): 627-37.
  17. Koren M.J., Hunninghake D.B. Clinical Outcomes in Managed Care Patients with Coronary Heart Disease Treated Aggressively in LipidLowering Disease Management Clinics. The ALLIANCE Study. J. Am. Coll. Cardiol. 2004; 44: 1772-9.
  18. Schwartz G.G., Oliver M.F., Ezekowitz M.D. et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am. J. Cardiol. 1998; 81: 578-81.
  19. Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA-ACS Randomized Trial. J. Am. Coll. Cardiol. 2007; 49: 1272-8.
  20. Gibson C.M., Pride Y.B., Hochberg C.P., Sloan S. et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22. J. Am. Coll. Cardiol. 2009; 54(24): 2290-5.
  21. Okazaki S., Yokoyama F., Miyauchi К. Early Statin Treatment in Patients with Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis during Half a Year After Coronary Event: The ESTABLISH Study. Circulation. 2004; 110: 1061-8.
  22. Nissen S., Nicholls S., Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTERIOD trial. JAMA. 2006; 295: 1556-65.
  23. Fellstrom В., Zannad F., Schmieder R. et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr. Control. Trials Cardiovasc. Med. 2005; 6: 9.
  24. Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and base-line characteristics. Eur. J. Heart Fail. 2005; 7: 1059-69.
  25. Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007, 357: 2248-2261. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSIHF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 1231-9.
  26. Clearfield M.B., Amerena J., Bassand J.P., Hernandez-Garcia H.R., Miller S.S., Sosef F.F.M. et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006; 7: 35.
  27. Ballantyne C.M., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low density lipoprotein cholesterol and non-high density lipoprotein cholesterol targets in high risk patients. The MERCURY II (Measuring Effective Reduction in Cholesterol Using Rosuvastatin therapy II) trial. J. Am. Coll. Cardiol. 2008; 52: 626-32.
  28. Leiter L.A., Rosenson R.S., Stein E., Reckless J., Schulte K.L., Schleman M. et al. On behalf of the POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg vs atorvastatin 80 mg in high risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007; 194: 154-64.
  29. Xu M., Yuan G., Wei F. Effect of atorvastatin in patients with chronic heart failure - in-sights from randomized clinical trials. Arch. Med. Sci. 2010; 6(6): 866-73.
  30. Lipinski M.J., Cauthen C.A., Biondi-Zoccai G.G. et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am. J. Cardiol. 2009; 15; 104(12): 1708-16.
  31. Hou W., Lv J., Perkovic V., Yang L. et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur. Heart J. 2013; 34(24): 1807-17.
  32. Palmer S.C., Navaneethan S.D., Craig J.C. et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. 2014; (5): CD007784.
  33. Palmer S.C., Navaneethan S.D., Craig J.C. et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst. Rev. 2013; (9): CD004289.
  34. Palmer S.C., Navaneethan S.D., Craig J.C., et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst. Rev. 2014; (1): CD005019.
  35. Savarese G., Musella F., Volpe M., Paneni F., Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: a metaanalysis. Int. J. Cardiol. 2013; 167: 2482e2489.
  36. Wu Y., Wang Y., An C., Dong Z., Liu H., Zhang Y., Zhang M., An F. Effects of rosuvastatin and atorvastatin on renal function: metaanalysis. Circ. J. 2012; 76: 1259e1266.
  37. Nakagami H., Shimosato T., Shimamura M., Morishita R. Rosuvastatin Ameliorates Obesity and Proteinuria in Zucker Diabetic Fatty Rats Immunology. Endocr. Metabol. Ag. Medic. Chem. 2013; 13(2): 144-9(6).
  38. Shepherd J., Kastelein J.J., Bittner V., Deedwania P., Breazna A., Dobson S., Wilson D.J., Zuckerman A., Wenger N.K. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J. Am. Coll. Cardiol. 2008; 51(15): 1448-54.
  39. Preiss D., Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr. Opin. Lipidol. 2011; 22: 460-6.
  40. Brunzell J.D., Davidson M., Furberg C.D. et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation. Diabet. Care. 2008; 31(4): 811-22.
  41. Carter A.A., Gomes T., Camacho X. et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346: 2610.
  42. Maki K.C., Ridker P.M., Brown W.V. et al. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J. Clin. Lipidol. 2014; 8(Suppl. 3): 17-29.
  43. Sattar N., Preiss D., Murray H.M. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 27, 375(9716): 735-42.
  44. Sugiyama T., Tsugawa Y., Tseng C.H. et al. Different time trends of caloric and fat in-take between statin users and nonusers among US adults: gluttony in the time of statins? JAMA. Intern. Med. 2014; 174(7): 1038-45.
  45. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabet. Care. 2004; 27(6): 1496-504.
  46. Barakat L., Jayyousi A., Bener A., Zuby B., Zirie M. Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients. ISRN Pharmacol. 2013; 2013: 146579.
  47. Hiro T., Kimura T., Morimoto T. et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome - serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ. J. 2010; 74: 1165-74.
  48. Jones P.H., Davidson M.H., Stein E.A. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol. 2003; 92(2): 152-60.
  49. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabet. Care. 2004; 27(6): 1496-504.
  50. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685-96.
  51. Lai C.L., Chou H.W., Chan K.A., Lai M.S. Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus. Am. J. Cardiol. 2015; 115(5): 619-24.
  52. de Zeeuw D., Anzalone D.A., Cain V.A. et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet. Diabet. Endocrinol. 2015; 3(3): 181-90.
  53. Antonelli Incalzi A.R., Fuso L., De Rosa M. et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10(12): 2794-800.
  54. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514-9.
  55. Karoli N.A., Rebrov A.P. Comorbidity in patients with chronic obstructive pulmonary disease: a role of cardiovascular disorders. Rational Pharmacotherapy in Cardiology. 2009; 5(4): 9-16. (In Russ.) Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная фармакотерапия в кардиологии. 2009; 5(4): 9-16.
  56. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple case coding analysis. Eur. Respir. J. 2003; 22(5): 809-14.
  57. Zhang W., Zhang Y., Li C.W. et al. Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials. Chest. 2017; 152(6): 1159-68.
  58. Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222-32.
  59. Ridker P.M., Danielson E., Fonseca F.A.H. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Eng. J. Med. 2008; 359: 2195-207.
  60. Chello M., Patti G., Candura D. et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit. Care Med. 2006; 34: 660-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies